|Day Low/High||43.52 / 45.93|
|52 Wk Low/High||34.53 / 96.59|
Investors considering a purchase of Spark Therapeutics Inc shares, but tentative about paying the going market price of $23.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $20 strike, which has a bid at the time of this writing of $3.50.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
While the world's attention turns to Pennsylvania on February 2 nd for Groundhog Day prognostications about continuing winter weather, investment professionals will gather in Philadelphia on February 3 rd for the 2016...
Join Emerald Asset Management for the 23 rd annual Groundhog Day Investment Forum on February 3 rd in Philadelphia.
My biotech and pharma superlatives for 2015.
The Children's Hospital of Philadelphia Foundation to be a Selling Stockholder
Presentation Highlights Positive Trend in Visual Acuity, Together With Highly Statistically Significant Positive Results in Primary and First Two Secondary Efficacy Endpoints
Preclinical Data Published in Science Translational Medicine Demonstrate Delay in Onset and Progression of a Form of Batten Disease
Insiders at these companies have been scooping up shares of their own stock lately.
Apple (AAPL) shares bucked the upward trend in tech stocks after Citigroup analysts cut iPhone sales estimates on Monday.
The shares of Spark Therapeutics are surging after the company announced that its lead gene therapy product candidate had met its primary endpoint in a Phase 3 trial.
Cramer says to wait on Johnson Controls and avoid Jacobs Engineering.
Cramer says these five groups must be approached with caution.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
These stocks look poised to break out and trade higher from current levels.
Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.